Cardiovascular and Metabolic Archives | Page 2 of 3 | Report Store

Diabetes and diabetic complications
Other metabolic diseases
Anemias
Hypertension
Thrombosis
Bleeding disorders
Cerebrovascular diseases
Heart failure
Ischemic heart disease

Sort by Relevance

Click to order products descending

Display 15 Products per page

Market Spotlight: Atrial Fibrillation

$1,318.00

This Market Spotlight report covers the Atrial Fibrillation market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
October 21, 2021
Find out more
Disease Analysis: Type 2 Diabetes
Read More
Diabetes mellitus is a group of metabolic disorders which are characterized by hyperglycemia (elevated blood glucose levels) due to insufficient insulin secretion, which in type 2 diabetes occurs in the setting of insulin insensitivity.
October 20, 2021
Find out more
Market Spotlight: Chemotherapy-Induced Anemia

$1,318.00

This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
October 14, 2021
Find out more
Disease Analysis: Anemia in Chronic Kidney Disease
Read More
Anemia in chronic kidney disease (CKD), defined as a reduction in red blood cells (RBCs) or hemoglobin levels, often results from decreased levels of erythropoietin and increased levels of hepcidin. Erythropoietin is primarily produced in the kidneys and increases the production of RBCs by acting on precursor cells. H
September 24, 2021
Find out more
Market Spotlight: Duchenne Muscular Dystrophy (DMD)

$1,318.00

This Market Spotlight report covers the Duchenne muscular dystrophy market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
September 23, 2021
Find out more
Market Spotlight: Renal Disease

$1,318.00

This Market Spotlight report covers the Renal Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
September 16, 2021
Find out more
Market Spotlight: Sickle Cell Anemia

$1,318.00

This Market Spotlight report covers the Sickle Cell Anemia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals.
June 10, 2021
Find out more
Disease Analysis: Chronic Heart Failure
Read More
Chronic heart failure (CHF) is a progressive condition in which the heart muscle is unable to pump enough blood to meet the needs of the body. CHF can result from functional abnormalities such as ventricular dysfunction or arrhythmias, or structural disorders of the myocardium or valves.
March 31, 2021
Find out more
Diabetes Management: Blood Glucose Monitoring Devices Market (2021)

$4,750.00

This report provides a detailed presentation of diabetes and blood glucose monitoring devices, including standard fingerstick-based blood glucose meters (BGMs) and new sensor-based continuous glucose monitoring systems (CGMs) that attach to the body and monitor blood glucose 24 hours a day
March 31, 2021
Find out more
Non-alcoholic steatohepatitis (NASH) Market and Forecast Analysis to 2038
Read More
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of patients who have fatty liver in the absence of significant alcohol consumption. NAFLD patients are often segmented into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) patients. NAFLD diagnosis requires evidence of hepatic steatosis and lack of secondary causes of liver fat accumulation such as substantial alcohol consumption, long-term use of a steatogenic medicine, or monogenic hereditary disorders. NASH is defined as the presence of >5% hepatic steatosis and inflammation with hepatocyte injury, with or without fibrosis. Although the presence of fibrosis is not required for a diagnosis of NASH, fibrosis is present in over 80% of NASH patients. For this reason, NASH patients are often further segmented by their fibrosis stage.
January 28, 2021
Find out more
Diabetes Management: Insulin Pumps Market (2020)

$4,750.00

This report provides an overview of diabetes, automated insulin pump systems, and a comprehensive market and competitive analysis.
December 30, 2020
Find out more
Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Northeast

$599.00

Key topics discussed in this specialist interview with a US-based key opinion leader (KOL) include the diagnostic landscape in NASH and future market trends, with a focus on GLP-1 agonists, FGF 19/21 analogs, and FXR agonists.
August 28, 2020
Find out more
Digital Health: Diabetes Apps and Virtual Coaching

$2,250.00

Smartphone-based digital health technologies are expected to transform the diabetes management market over the next decade by substantially improving diabetes outcomes and reducing healthcare costs. These technologies are engaging and empowering patients, improving glycemic control, and lowering complications. Digital health technologies are defined in this report as: diabetes smartphone apps integrated with blood glucose monitoring devices (both standard blood glucose meters and continuous glucose monitoring systems) and personalized “virtual diabetes coaching” services.
March 10, 2020
Find out more
Transcatheter Embolization and Occlusion Devices

$4,750.00

This comprehensive medical market and technology report provides an overview and in-depth market analysis of the global market for transcatheter embolization and occlusion devices.
February 25, 2020
Find out more
Diabetes Management: Blood Glucose Monitoring Devices Market

$4,750.00

According to the International Diabetes Federation (IDF), approximately 425 million adults (20-79 years of age) have diabetes worldwide, and this number is expected to rise nearly 50% to approximately 629 million by 2045. More than 1.25 million people have type 1 diabetes in the US alone.
December 19, 2019
Find out more

Cardiovascular and Metabolic

Market Spotlight: Atrial Fibrillation

Disease Analysis: Type 2 Diabetes

Market Spotlight: Chemotherapy-Induced Anemia

Disease Analysis: Anemia in Chronic Kidney Disease

Market Spotlight: Duchenne Muscular Dystrophy (DMD)

Market Spotlight: Renal Disease

Market Spotlight: Sickle Cell Anemia

Disease Analysis: Chronic Heart Failure

Diabetes Management: Blood Glucose Monitoring Devices Market (2021)

Non-alcoholic steatohepatitis (NASH) Market and Forecast Analysis to 2038

Diabetes Management: Insulin Pumps Market (2020)

Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Northeast

Digital Health: Diabetes Apps and Virtual Coaching

Transcatheter Embolization and Occlusion Devices

Diabetes Management: Blood Glucose Monitoring Devices Market